Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136982

Published: 2020

Journal Articles

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136258

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 3874.

https://doi.org/10.1182/blood-2019-125558

Published: 2019

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Blood (2019) 134 (Supplement_1): 4580.

https://doi.org/10.1182/blood-2019-129880

Published: 2019

Journal Articles

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Blood (2019) 134 (Supplement_1): 2687.

https://doi.org/10.1182/blood-2019-131733

Published: 2019

Journal Articles

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Blood (2019) 134 (Supplement_1): 888.

https://doi.org/10.1182/blood-2019-127822

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 509.

https://doi.org/10.1182/blood-2019-128049

Published: 2019

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Evangelos Terpos, MD PhD, Ramón García-Sanz, MD PhD, Kazuyuki Shimizu, MD, Wolfgang Willenbacher, MD PhD, Anthony Glennane, MD, Tian Dai, PhD, Walraud Pasteiner, PhD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 606.

https://doi.org/10.1182/blood-2019-127290

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data

Alejandro Medina, Cristina Jiménez, PhD, Maria E Sarasquete, PhD, Noemi Puig, MD PhD, Ana Balanzategui, Miguel Alcoceba, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Garcia-Alvarez, B.Sc., Isabel Prieto-Conde, PhD, Carmen Chillon, PhD, Enrique M. Ocio, MD, Norma C. Gutierrez, MD PhD, Maria-Victoria Mateos, MD PhD, Joaquin Martínez-López, MD PhD, Juan Jose Lahuerta, MD PhD, Jesús F San-Miguel, MD, Marcos González, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2018-99-114627

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Carmen Martinez, MD PhD, Cecilia Carpio, MD, Inmaculada Heras, Eduardo Ríos Herranz, MD, Joan Buch, Antonio Gutierrez, MD PhD, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, PhD, Rosalia Alonso, Joan Bargay, MD PhD, Cristina Barrenetxea Lekue, PhD, Narvaez Javier, Manuel Espeso de Haro, MD, Luis Palomera, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2018-99-115774

Published: 2018

Journal Articles

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 474.

https://doi.org/10.1182/blood-2018-99-115050

Published: 2018

Journal Articles

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Blood (2018) 132 (Supplement 1): 112.

https://doi.org/10.1182/blood-2018-99-113312

Published: 2018

Journal Articles

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Miguel Alcoceba, PhD, Maria Garcia-Alvarez, B.Sc., Anna Puiggros, PhD, Luis Espinosa-Hevia, PhD, Andrea Gómez-Llonín, B.Sc., Almudena Navarro, MD, Jose Maria Bastida, MD PhD, Norma C. Gutierrez, MD PhD, Jose A. Garcia-Marco, MD PhD, Blanca Espinet, PhD, Ramón García-Sanz, MD PhD, Marcos González, MD PhD

Blood (2018) 132 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2018-99-114995

Published: 2018

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only